Advertisement: TTP Killer 50
5 July, 2018 - 12:25 By News Desk

Qkine

Qkine builds on expertise in protein purification and structural biology developed at Cambridge University and collaborations with the stem cell community. 

It seeks to address the need for high-quality growth factors for regenerative medicine, and to innovate to tackle challenges in stem cell science.

Earlier this year, the company closed a seed investment round for an undisclosed sum supported by Cambridge Enterprise, the university’s commercialisation arm, and a team of five angels led by former Abcam executive Jim Warwick.

The company was founded by Dr Marko Hyvönen (pictured) and Dr Catherine Onley.

qkine.com

Newsletter Subscription

Stay informed of the latest news and features